
1. pathologe. 2018 feb;39(1):57-64. doi: 10.1007/s00292-017-0382-x.

[munich nomenclature iii: classification according risk : follow-up for
conspicuous squamous findings].

[article german]

marquardt k(1), ziemke p(2).

author information: 
(1)praxis für pathologie, güstrower str. 34, 19055, schwerin, deutschland.
katrin.marquardt.schwerin@gmail.com.
(2), potsdam, deutschland.

aim: present study evaluates risk progression cytologic diagnoses
which require immediate therapy need follow-up. presented data 
can contribute risk-adapted management strategies, according munich
nomenclature iii.
methods: january 2014 march 2016, 3396 women diagnosed group 
ii-p, iiid1, iii-p, iiid2, iva-p, ivb-p, v‑p represent study
population. follow-up information subsequent cytologic histologic
findings collected july 2017. initial cytologic diagnosis, the
cumulative risk cin2+ cin3+ risk persistent pathologic findings
was calculated.
results: cumulative risk cin2+ initial findings ii-p, iiid1, iii-p,
and iiid2 calculated 7.3, 17.1, 46.3, 62.4%, respectively, a mean
observation period 24.4, 21.1, 15.6, 14.3 months. cumulative risk of
cin3+ (%) determined 5.0, 9.3, 37.6, 45.8. persistent cytologic
diagnoses ii-p, iiid1, iii-p, iiid2, risk cin2+ increases
significantly second result (0 3.6, 0.21 3.6, 7.2 58.3, and
8.1 64.7%). risk cin2+ cin3+ group iii-p significantly higher
for women <35 years <30 years compared women higher age. no
significant age-dependent differences findings ii-p, iiid1, iiid2.
conclusions: munich nomenclature iii classifies cytologic findings according 
to risk. diagnostic groups munich nomenclature iii provide a solid
basis a risk-adapted clinical management, cytologic history the
individual patient taken account.

doi: 10.1007/s00292-017-0382-x 
pmid: 28993907  [indexed medline]

